Literature DB >> 30948894

Prognostic Utility of Cyclin D1 in Invasive Breast Carcinoma.

Tamanna Parvin1, Chhanda Das1, Manoj Choudhury1, Bitan Kumar Chattopadhyay2, Madhumita Mukhopadhyay1.   

Abstract

Invasive breast carcinoma is the most common cancer among women worldwide. Increase in early detection of breast carcinoma by different diagnostic modalities led to decrease in cancer-related mortality and morbidity. Multiple factors and genes are implicated in breast cancer pathogenesis. Cyclin D1 is an important cell cycle regulatory protein involved in carcinogenesis of various human cancers including breast cancer. Aims of the present study were to evaluate the prognostic importance of cyclin D1 expression in invasive breast carcinoma and its correlation with other prognostic and predictive factors. Patients undergoing mastectomy for breast carcinoma were selected from January 2016 to June 2017 in a tertiary care hospital. Clinical history including demographic parameters was collected in the study pro forma. Immunohistochemical staining for ER, PgR, HER2 and cyclin D1 was performed on all cases. The clinicopathological parameters like age, tumour size, histologic grade, histological type, lymphovascular invasion, axillary lymph node metastasis, ER, PgR and HER2 status were compared and correlated with cyclin D1 expression. Cyclin D1 expression found in 60% cases of breast carcinoma. Expression of cyclin D1 showed a highly significant correlation with histological grade (p = 0.000). Cyclin D1 expression showed significant correlation (p = 0.000) with molecular subtypes. There was also significant correlation between cyclin D1 expression and ER (p = 0.000) and PgR (p = 0.010) status. This study revealed significant cyclin D1 expression in low grade, well-differentiated breast cancer. Therefore, we found cyclin D1 as a favourable prognostic marker in breast carcinoma.

Entities:  

Keywords:  Breast cancer; Cyclin D1; Immunohistochemistry

Year:  2018        PMID: 30948894      PMCID: PMC6414594          DOI: 10.1007/s13193-018-0839-2

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  27 in total

Review 1.  Cyclin D1 in breast cancer pathogenesis.

Authors:  Andrew Arnold; Alexandros Papanikolaou
Journal:  J Clin Oncol       Date:  2005-06-20       Impact factor: 44.544

2.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.

Authors:  Mi-Jung Kim; Jae Y Ro; Sei-Hyun Ahn; Hak Hee Kim; Sung-Bae Kim; Gyungyub Gong
Journal:  Hum Pathol       Date:  2006-07-18       Impact factor: 3.466

3.  A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer.

Authors:  Jérôme Eeckhoute; Jason S Carroll; Timothy R Geistlinger; Maria I Torres-Arzayus; Myles Brown
Journal:  Genes Dev       Date:  2006-09-15       Impact factor: 11.361

4.  Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients.

Authors:  Tae Sook Hwang; Hye Seung Han; Yun Chul Hong; Hun Jae Lee; Nam-Sun Paik
Journal:  Pathol Int       Date:  2003-02       Impact factor: 2.534

5.  Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients.

Authors:  Yoshihisa Umekita; Yasuyo Ohi; Yoshiatsu Sagara; Hiroki Yoshida
Journal:  Int J Cancer       Date:  2002-03-20       Impact factor: 7.396

Review 6.  Cyclins and breast cancer.

Authors:  Robert L Sutherland; Elizabeth A Musgrove
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

7.  Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis.

Authors:  Jorge S Reis-Filho; Kay Savage; Maryou B K Lambros; Michelle James; Dawn Steele; Robin L Jones; Mitch Dowsett
Journal:  Mod Pathol       Date:  2006-04-28       Impact factor: 7.842

Review 8.  Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models.

Authors:  Robert L Sutherland; Elizabeth A Musgrove
Journal:  Breast Cancer Res       Date:  2001-11-30       Impact factor: 6.466

Review 9.  Prognostic molecular markers in early breast cancer.

Authors:  Francisco J Esteva; Gabriel N Hortobagyi
Journal:  Breast Cancer Res       Date:  2004-03-11       Impact factor: 6.466

10.  Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.

Authors:  M Stendahl; A Kronblad; L Rydén; S Emdin; N O Bengtsson; G Landberg
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

View more
  2 in total

1.  PRMT5 Promotes Aerobic Glycolysis and Invasion of Breast Cancer Cells by Regulating the LXRα/NF-κBp65 Pathway.

Authors:  Xiao Han; Linlin Wei; Bin Wu
Journal:  Onco Targets Ther       Date:  2020-04-21       Impact factor: 4.147

2.  Anti-cancer therapeutic benefit of red guava extracts as a potential therapy in combination with doxorubicin or targeted therapy for triple-negative breast cancer cells.

Authors:  Hsiao-Chun Liu; Chien-Chuan Chiang; Ching-Hsiang Lin; Chien-Sheng Chen; Chyou-Wei Wei; Shu-Yu Lin; Giou-Teng Yiang; Yung-Luen Yu
Journal:  Int J Med Sci       Date:  2020-04-06       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.